SynthesisBMC cancer2011
FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.
Synthesis in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Pooled it
- Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.Oncotarget · 2017Pooled it
- Ethnic background and genetic variation in the evaluation of cancer risk: a systematic review.PloS one · 2014Pooled it
- XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: a meta-analysis.Prostate cancer and prostatic diseases · 2011Pooled it
- Article
- FGFR4 p.Gly388Arg polymorphism in PBMCs of LAM patients: findings of a pilot study.Frontiers in medicine · 2025Article
- Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer.Scientific reports · 2021Article
- Article
- Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.Breast cancer research and treatment · 2020Article
- Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.Frontiers in cell and developmental biology · 2020Review
- Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas.World journal of clinical oncology · 2019Article
- The Role of Polymorphisms in Genes of PI3K/Akt Signaling Pathway on Prostate.Journal of Cancer · 2019Article
- Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population.Scientific reports · 2016Article
- Deguelin-induced blockade of PI3K/protein kinase B/MAP kinase signaling in zebrafish and breast cancer cell lines is mediated by down-regulation of fibroblast growth factor receptor 4 activity.Pharmacology research & perspectives · 2016Article
- Article
- Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- A kinome-targeted RNAi-based screen links FGF signaling to H2AX phosphorylation in response to radiation.Cellular and molecular life sciences : CMLS · 2015Article
- Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.Apoptosis : an international journal on programmed cell death · 2013Review
- Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.World journal of gastroenterology · 2013Article
- The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes.Cell metabolism · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibroblast growth factor receptor 4 (FGFR4) displays multiple biological activities, including mitogenic and angiogenic activity, and plays important roles in the etiology and progression of prostate cancer. Gly388Arg polymorphism in FGFR4 gene has been reported to be involved in prostate cancer incidence and aggressiveness in several studies. To derive a more precise estimation of the relationship, a meta-analysis was performed.
methodsOdds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association.
resultsThe Arg388 allele increased prostate cancer risk compared with Gly388 allele (OR = 1.17, 95% CI = 1.07-1.29). When stratified by race, there was a significantly increased prostate cancer risk in Asian and Caucasian populations. Moreover, prostate cancer patients with Arg/Arg genotype had a 1.34-fold increased risk of advanced prostate cancer (95% CI: 1.03-1.74) compared with those with Gly/Gly+Gly/Arg genotype.
conclusionThis meta-analysis showed the evidence that FGFR4 Gly388Arg polymorphism was associated with an increased risk of prostate cancer development and progression, suggesting that FGFR4 Gly388Arg polymorphism could be a marker for prostate cancer development and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.